Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | STK4 | Q13043 | 1/20 | 0.47 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632946 | 0.90 | IKBKB (0.45) | IKBKBMAP4K1STK4CA12CA1 | |
| SCHEMBL1633319 | 0.90 | JAK3 (0.49) | CAMK2DCDK2AURKACCNE1CCNA2 | |
| SCHEMBL1632828 | 0.87 | IKBKB (0.48) | IKBKBSTK4CA12CA1CA2 | |
| SCHEMBL1634287 | 0.86 | IGF1R (0.47) | IKBKBMAP4K1CAMK2DMAP4K3CDK2 | |
| SCHEMBL1632932 | 0.83 | SYK (0.51) | MAP4K1STK4MAP4K3CA12CA1 | |
| SCHEMBL1634873 | 0.82 | MAP4K1 (0.44) | MAP4K1CAMK2DMAP4K3 | |
| SCHEMBL1633471 | 0.81 | CDK2 (0.47) | MAP4K1CDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL1634267 | 0.81 | CDK4 (0.50) | MAP4K1MAP4K3CDK2AURKACCNA2 | |
| SCHEMBL1634285 | 0.81 | MAP4K1 (0.55) | MAP4K1MAP4K3CDK2AURKACCNE1 | |
| SCHEMBL1633099 | 0.81 | IKBKB (0.65) | IKBKBSTK4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | IKBKB 980/4885MAP4K1 48/4885CAMK2D 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.